Renaissance Capital logo

Kenvue Priced, NYSE: KVUE

Consumer health products unit spun out of J&J.

Industry: Consumer Staples

Latest Trade: $21.45 0.00 (0.0%)

First Day Return: +22.3%

Return from IPO: -2.5%

Industry: Consumer Staples

We are the world’s largest pure-play consumer health company by revenue with $15.1 billion in net sales in 2021. We combine the power of science with meaningful human insights and digital-first capabilities, which we believe empowers approximately 1.2 billion people to live healthier lives every day. Our differentiated portfolio of iconic brands -- including Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec and Nicorette -- is built for moments that uniquely matter to our consumers and, we believe, drives positive health outcomes around the world. We are a global leader at the intersection of healthcare and consumer goods, with a portfolio of iconic brands, operating in some of the most attractive categories in consumer health from both a growth and profitability perspective. Our consumer health portfolio includes self care, skin care and beauty and essential personal care products, which reflect categories that we believe allow consumers across the world to realize the extraordinary power of everyday care. We hold leadership positions across a $365 billion consumer health market that we expect to grow at a compounded annual growth rate (“CAGR”) of 3% to 4% globally through 2025.
more less
IPO Data
IPO File Date 01/04/2023
Offer Price $22.00
Price Range $20.00 - $23.00
Offer Shares (mm) 172.8
Deal Size ($mm) $3,802
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 05/03/2023
Offer Price $22.00
Price Range $20.00 - $23.00
Offer Shares (mm) 172.8
Deal Size ($mm) $3,802
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Goldman Sachs
J.P. Morgan
more
Company Data
Headquarters Skillman, NJ, United States
Founded 1886
Employees 22,200
Website www.kenvue.com

Kenvue (KVUE) Performance